Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499159 · ClinicalTrials.gov registry record · Phase 4
Pain Management in Response to Exparel vs. Standard Bupivicaine
A Phase 4 study, sponsored by Inova Health Care Services.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT02499159: Completed Phase 4 study, sponsored by Inova Health Care Services.
NCT02499159 is a Phase 4 study that has completed, run by Inova Health Care Services. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02499159, a Phase 4 study, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications. Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels using a visual pain scale, and to assess how much pain medication was consumed.
Primary Outcome
Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets.
Interventions
- DRUG Liposomal Bupivicaine
- DRUG 0.25% standard bupivicaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
What the finished NCT02499159 record still lists
NCT02499159 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivicaine is the first listed.
NCT02499159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02499159 about?
NCT02499159 is a clinical study titled "Pain Management in Response to Exparel vs. Standard Bupivicaine". This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications. Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels...
What is the current status of trial NCT02499159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2014-12. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02499159?
The interventions under investigation include: Liposomal Bupivicaine (DRUG), 0.25% standard bupivicaine (DRUG).
Who is sponsoring clinical trial NCT02499159?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02499159's enrollment target sits among peer trials
100 770th of 2000 higher than 1,148 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia